After Recent MDMA Rejection, Lykos Criticizes FDA Ad Comm Conduct

Psychedelic drug company Lykos Therapeutics is blasting FDA’s advisory committee process in new comments saying advisors’ vote against approval of its application was influenced by inappropriate off-topic discussion, after FDA’s rejection of the treatment led to backlash from pharmaceutical skeptics including a prominent new ally of the Trump campaign. The comments follow FDA’s June public meeting on advisory committee reform. Lykos said its feedback is informed by its recent experience as the sponsor in an advisory committee meeting discussing midomafetamine...